Table 4 Most common adverse events in the clarithromycin and placebo group
Clarithromycin group, No = 27 | Placebo group, No = 31 | |||
|---|---|---|---|---|
Any grade | Grade 3 or 4 | Any grade | Grade 3 or 4 | |
Hematologic events | ||||
Thrombocytopenia | 11 (40.7%) | 2 (7.4%) | 7 (22.6%) | 0 |
Anemia | 12 (44.4%) | 2 (7.4%) | 11 (35.5%) | 0 |
Neutropenia | 11 (40.7%) | 1 (3.7%) | 13 (41.9%) | 0 |
Gastrointestinal events | ||||
Typhlitis and perforation of colon | 2 (7.4%) | 2 (7.4%) | 1 (3.2%) | 1 (3.2%) |
Paralytic ileus | 2 (7.4%) | 2 (7.4%) | 0 | 0 |
Constipation | 6 (22.2%) | 1 (3.7%) | 5 (16.1%) | 0 |
Diarrhea | 4 (14.8%) | 3 (11.1%) | 5 (16.1%) | 1 (3.2%) |
Dyspepsia | 3 (11.1%) | 0 | 1 (3.2%) | 0 |
Nausea | 5 (18.5%) | 0 | 6 (19.4%) | 0 |
Infections | ||||
Respiratory tract infection | 5 (18.5%) | 2 (7.4%) | 8 (25.8%) | 5 (16.1%) |
Urinary tract infection | 3 (11.1%) | 1 (3.7%) | 5 (16.1%) | 1 (3.2%) |
Septicemia | 5 (18.5%) | 5 (18.5%) | 1 (3.2%) | 1 (3.2%) |
Other infections | 6 (22.2%) | 4 (14.8%) | 9 (29.0%) | 5 (16.1) |
Oral candidiasis | 7 (25.9%) | 1 (3.7%) | 1 (3.2%) | 0 |
Nervous system disorders | ||||
Peripheral sensory neuropathy | 15 (55.6%) | 0 | 8 (25.8%) | 0 |
Dizziness | 4 (14.8%) | 1 (3.7%) | 3 (9.7%) | 0 |
Other conditions | ||||
Peripheral edema | 11 (40.7%) | 1 (3.7%) | 7 (22.6%) | 1 (3.2%) |
Hypotension | 4 (14.8%) | 2 (7.4%) | 1 (3.2%) | 0 |
Fatigue | 4 (14.8%) | 1 (3.7%) | 3 (9.7%) | 0 |
Rash | 2 (7.4%) | 0 | 4 (12.9%) | 0 |
Insomnia | 2 (7.4%) | 0 | 6 (19.4%) | 0 |
Weight loss | 3 (11.1%) | 0 | 1 (3.2%) | 0 |
Mucositis | 2 (7.4%) | 0 | 4 (12.9%) | 0 |
Psychiatric symptomsa | 5 (18.5%) | 1 (3.7%) | 2 (6.5%) | 1 (3.2%) |